Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A2 | Q12908 | 1/20 | 0.60 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.60 |
| ▸ | SLC10A6 | Q3KNW5 | 1/20 | 0.60 |
| ▸ | GPR27 | Q9NS67 | 5/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.54 |
| ▸ | LMNA | P02545 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | CRHBP | P24387 | 1/20 | 0.50 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.50 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.48 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7214441 | 0.95 | GPR27 (0.57) | SLC10A2SLC10A1SLC10A6GPR27KMT2A | |
| SCHEMBL7208733 | 0.93 | SLC10A6 (0.71) | SLC10A2SLC10A1SLC10A6GPR27KMT2A | |
| SCHEMBL7128469 | 0.86 | SLC10A2 (0.60) | SLC10A2SLC10A1SLC10A6GPR27KMT2A | |
| SCHEMBL7128140 | 0.84 | SLC10A6 (0.61) | SLC10A2SLC10A1SLC10A6GPR27KMT2A | |
| SCHEMBL27575113 | 0.83 | SLC10A6 (0.56) | SLC10A2SLC10A1SLC10A6GPR27KMT2A | |
| SCHEMBL7120319 | 0.83 | SLC10A6 (0.76) | SLC10A2SLC10A1SLC10A6GPR27KMT2A | |
| SCHEMBL7212991 | 0.81 | SLC10A6 (0.73) | SLC10A2SLC10A1SLC10A6GPR27KMT2A | |
| SCHEMBL7116008 | 0.81 | SLC10A6 (0.85) | SLC10A2SLC10A1SLC10A6GPR27KMT2A | |
| SCHEMBL7208746 | 0.80 | TSHR (0.58) | SLC10A2SLC10A1SLC10A6KMT2ALMNA | |
| SCHEMBL7213174 | 0.80 | SLC10A6 (0.61) | SLC10A2SLC10A1SLC10A6GPR27KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030216449-A1 | Phosphate transport inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-11-20 | — | — | US | claimed |
| CN-1429108-A | Phosphate transport inhibitors | SMITHKLINE BEECHAM CORP (US) | 2003-07-09 | — | — | CN | claimed |
| EP-1187531-A4 | MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2003-05-28 | — | — | EP | claimed |
| US-6458845-B1 | METHOD OF ANTAGONIZING A MACROPHAGE SCAVENGER RECEPTOR COMPRISING ADMINISTERING TO A SUBJECT IN NEED OF TREATMENT AN EFFECTIVE AMOUNT OF AN N-PHENYL-2-(3-TRIFLUOROMETHYLPHENYLSULFONAMIDO)BENZAMIDE, A | SMITHKLINE BEECHAM CORPORATION | 2002-10-01 | — | — | US | claimed |
| CN-1358062-A | Macrophage scavenger receptor antagonists | SMITHKLINE BEECHAM CORP (US) | 2002-07-10 | — | — | CN | claimed |
| EP-1202729-A1 | PHOSPHATE TRANSPORT INHIBITORS | SmithKline Beecham Corporation (US) | 2002-05-08 | — | — | EP | claimed |
| EP-1187531-A1 | MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2002-03-20 | — | — | EP | claimed |
| WO-2001098264-A1 | MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-12-27 | — | — | WO | claimed |
| WO-2001087294-A1 | PHOSPHATE TRANSPORT INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-11-22 | — | — | WO | claimed |
| WO-2001005398-A1 | PHOSPHATE TRANSPORT INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-01-25 | — | — | WO | claimed |
| WO-2000078145-A1 | MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-12-28 | — | — | WO | claimed |
| US-20030216449-A1 | Phosphate transport inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-11-20 | — | — | US | disclosed |
| US-20030212074-A1 | Phosphate transport inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-11-13 | — | — | US | disclosed |
| CN-1429108-A | Phosphate transport inhibitors | SMITHKLINE BEECHAM CORP (US) | 2003-07-09 | — | — | CN | disclosed |
| US-6458845-B1 | METHOD OF ANTAGONIZING A MACROPHAGE SCAVENGER RECEPTOR COMPRISING ADMINISTERING TO A SUBJECT IN NEED OF TREATMENT AN EFFECTIVE AMOUNT OF AN N-PHENYL-2-(3-TRIFLUOROMETHYLPHENYLSULFONAMIDO)BENZAMIDE, A | SMITHKLINE BEECHAM CORPORATION | 2002-10-01 | — | — | US | disclosed |
| WO-2002028353-A2 | PHOSPHATE TRANSPORT INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-04-11 | — | — | WO | disclosed |
| WO-2001098264-A1 | MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-12-27 | — | — | WO | disclosed |
| WO-2001087294-A1 | PHOSPHATE TRANSPORT INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-11-22 | — | — | WO | disclosed |
| WO-2001082924-A1 | PHOSPHATE TRANSPORT INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-11-08 | — | — | WO | disclosed |
| WO-2001005398-A1 | PHOSPHATE TRANSPORT INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216449-A1 | Phosphate transport inhibitors | SLC34A2, SLC34A1, SLC34A3 | SLC10A2 57/4885SLC10A1 76/4885SLC10A6 19/4885 |
| US-20030212074-A1 | Phosphate transport inhibitors | SLC34A2, SLC34A3, SLC34A1 | SLC10A2 47/4885SLC10A1 81/4885SLC10A6 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.